Large-scale genome-wide association studies conducted over the last decade have
uncovered numerous genetic variants associated with cardiometabolic traits and risk factors …

There is now overwhelming evidence to support lowering LDL-c (low-density lipoprotein
cholesterol) to reduce cardiovascular morbidity and mortality. Statins are a class of drugs …

Mendelian randomisation (MR) studies allow a better understanding of the causal effects of
modifiable exposures on health outcomes, but the published evidence is often hampered by …

Objective The objective of this clinical practice guideline is to provide updated and new
evidence-based recommendations for the comprehensive care of persons with diabetes …

Cardiometabolic diseases are the leading cause of death worldwide. Despite a known
genetic component, our understanding of these diseases remains incomplete. Here, we …

The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing worldwide. In
some patients with NAFLD, isolated steatosis can progress to advanced stages with non …

One in 4 Americans> 40 years of age takes a statin to reduce the risk of myocardial
infarction, ischemic stroke, and other complications of atherosclerotic disease. The most …

Diabetes is the leading cause of severe health complications and one of the top 10 causes
of death worldwide. To date, diabetes has no cure, and therefore, it is necessary to take …

Results from genome-wide association studies (GWAS) can be used to infer causal
relationships between phenotypes, using a strategy known as 2-sample Mendelian …

Abstract Treatment with statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A
reductase, has proven beneficial preventive effects on cardiovascular events. However …